



## MEET THE SPEAKERS



**Dr Mark P. Lythgoe** Locum Medical Oncology Consultant (HPB, upper/lower GI and NETs) and Pharmacist, Imperial College Healthcare NHS Trust

**When:** Friday 17<sup>th</sup> April, 2pm

**Session:** UK Regulations and beyond

**Topic:** Imperial College Healthcare NHS Trust

Dr Mark P. Lythgoe is a Medical Oncologist and Pharmacist based at Imperial College Healthcare NHS Trust. After studying Pharmacy at Aston University, he graduated in Medicine from King's College London with dual distinctions. He subsequently undertook academic and clinical training in Medical Oncology across Northwest London and Brighton.

He has a broad range of academic interests, including translational clinical trial development, precision oncology, microbiome modulation as a therapeutic strategy, healthcare policy, and improving access to clinical trials.

Dr Lythgoe is a member of the ECMC JING Steering Committee and the London Global Cancer Week Steering Committee. He has also served for over 10 years on the Joint Formulary Committee for the British National Formulary (BNF). His work has been widely cited and has informed policy at both national and international levels, including contributions recognised by the WHO, IARC, EMA, and the UK Government.

He has received multiple awards, including the American Society of Clinical Oncology Merit Award in 2021 and 2022, and the Sylvia Lawler Prize on two occasions. He has authored more than 100 peer-reviewed publications in leading journals, including *The Lancet*, *The Lancet Oncology*, *The BMJ*, *JAMA Oncology*, *Nature Reviews Clinical Oncology*, *Journal of Clinical Oncology*, and *Trends in Pharmacological Sciences*.

Academic Profile: <https://www.imperial.ac.uk/people/m.lythgoe>

Google

scholar: <https://scholar.google.co.uk/citations?user=JypUP9cAAAAJ&hl=en>



## MEET THE SPEAKERS

[>> Find out more – Visit the Conference](#)

[Website](#)